Metraipolis › archive › dc_6ce06e55cc19

Time to Relapse Following Rituximab Therapy in Rheumatoid Arthritis and Its Determinants: A Single-Center Observational Study — Europe PMC PMID:42465139

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42465139
DOI
10.7759/cureus.110939
License (as archived)
solo-consultazione
Archived
2026-10-31T11:32:49.259Z
SHA-256 of the archived text
bf903f1850b0fd5e7ccfb8d032e7bf5e0cf82fd9ae718d83a51e707a35894eb0
Stable URL of this page
https://metraipolis.com/documento/dc_6ce06e55cc19

How to cite

Time to Relapse Following Rituximab Therapy in Rheumatoid Arthritis and Its Determinants: A Single-Center Observational Study — Europe PMC PMID:42465139 — Europe PMC (en), https://europepmc.org/article/MED/42465139 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6ce06e55cc19 (Metraipolis archive dc_6ce06e55cc19, sha256 bf903f1850b0fd5e7ccfb8d032e7bf5e0cf82fd9ae718d83a51e707a35894eb0)
BibTeX
@misc{dc6ce06e55cc19,
  title = {Time to Relapse Following Rituximab Therapy in Rheumatoid Arthritis and Its Determinants: A Single-Center Observational Study — Europe PMC PMID:42465139},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42465139},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6ce06e55cc19; sha256 bf903f1850b0fd5e7ccfb8d032e7bf5e0cf82fd9ae718d83a51e707a35894eb0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42465139. Agents can read the archived copy with the MCP tool read_document.